Breast cancer drug combo shows promise but study halted early
NCT ID NCT03101748
First seen Feb 17, 2026 · Last updated Jun 14, 2026 · Updated 18 times
Summary
This study tested a mix of targeted drugs (neratinib, pertuzumab, trastuzumab) and chemotherapy (paclitaxel) in people with advanced or inflammatory breast cancer. The goal was to find the best dose and see if the combination could shrink tumors before more chemo. The study was stopped early, but results helped understand side effects and tumor response in 34 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIA BREAST CANCER AJCC V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.